Showing results (361-370 of 523) with videos related to
Sort By:
Pageof 53
Cancers|December 17, 2020
Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung CancerArthur Geraud, Laura Mezquita, Edouard Auclin, et al.Pathology|June 4, 2024
Successive next-generation sequencing strategy for optimal fusion gene detection in non-small-cell lung cancer in clinical practiceSimon Garinet, Audrey Lupo, Thomas Denize, et al.European Journal of Cancer (Oxford, England : 1990)|September 25, 2023
Immunosuppressant mycophenolate mofetil for patients with steroid-refractory immune-related hepatitis induced by checkpoint inhibitors in oncologyEmily Alouani, Ariane Laparra, Audrey Perret, et al.Nature Communications|December 4, 2018
Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumoursAurélie Durgeau, Yasemin Virk, Gwendoline Gros, et al.Cancers|February 25, 2023
Prognostic Value of the Lung Immune Prognosis Index Score for Patients Treated with Immune Checkpoint Inhibitors for Advanced or Metastatic Urinary Tract CarcinomaPauline Parent, Edouard Auclin, Anna Patrikidou, et al.Plos One|April 3, 2026
PRognostic and predictive potential Of multiparametric dynamic whole-body 18F-FDG PET Imaging using a Long axial field-of-view (LAFOV) system for FIRST-line chemo-immunotherapy efficacy in advanced non-small cell lung cancer: PROFIL-1 study protocolMargaux Geier, Karim Amrane, David Bourhis, et al.BMC Cancer|July 17, 2016
Osteopontin and thrombospondin-1 play opposite roles in promoting tumor aggressiveness of primary resected non-small cell lung cancerMathieu Rouanne, Julien Adam, Aïcha Goubar, et al.NPJ Precision Oncology|February 16, 2024
EORTC-SPECTA Arcagen study, comprehensive genomic profiling and treatment adaptation of rare thoracic cancersMarco Tagliamento, Marie Morfouace, Charalambos Loizides, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 29, 2021
Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic AnalysisDavid Planchard, Benjamin Besse, Harry J M Groen, et al.The Lancet. Oncology|November 1, 2019
Lorlatinib in advanced ROS1-positive non-small-cell lung cancer: a multicentre, open-label, single-arm, phase 1-2 trialAlice T Shaw, Benjamin J Solomon, Rita Chiari, et al.Pageof 53